Developing a novel medical-grade microneedle patch to treat acne vulgaris

开发一种新型医用级微针贴片来治疗寻常痤疮

• 批准号: 10053162
• 金额: $ 43.99万
• 依托单位: IMPERIAL BIOSCIENCE LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10053162
• 关键词: Developing; novel; medical; grade; microneedle

Imperial Bioscience aims to be the first-to-market with their microneedle drug delivery product for medical use. Microneedle-mediated delivery is defined as the non-invasive delivery of medications through the skin surface. This is an alternative to hypodermic needles, which provides enhanced patient compliance. Expanded microneedle patch technology will become a highly valuable tool for delivering various pharmaceuticals with ease but without provoking skin irritation and side effects.Imperial Bioscience targets acne vulgaris. This project aims to understand the safety and efficacy of anti-acne drugs applied with microneedle technology in treating types of acne vulgaris that are historically considered less responsive and/or with side effects to oral medications. Work will develop a robust and stable platform for a novel means for delivering drug molecules directly into the skin where associated skin concerns originated; provide critical analysis of preclinical data for interactions of the cell types within the skin and mapping out safety and efficacy profile of microneedle technology associated with human skin inflammatory disorder of acne; leading to selection of a lead candidate for clinical study.

Imperial Bioscience的目标是成为其MicroNeedle药物输送产品以供医疗用途的第一到市场。微针介导的递送定义为通过皮肤表面的非侵入性药物递送。这是皮下注射针的替代方法，可提供增强的患者依从性。扩展的微针斑块技术将成为一种非常有价值的工具，可轻松提供各种药物，但不会引起皮肤刺激和副作用。帝国生物科学的目标是痤疮。该项目旨在了解使用微针技术施用的抗acne药物的安全性和功效，以治疗通常认为反应性较低和/或对口服药物的副作用的痤疮类型。工作将开发出一个可靠，稳定的平台，用于将药物分子直接传递到相关皮肤关注的皮肤中的新型手段。提供对皮肤中细胞类型相互作用的临床前数据的批判性分析，并绘制出与人类皮肤炎症性痤疮相关的微针技术的安全性和功效概况；导致选择临床研究的主要候选者。